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Abstract
Background: Partial thickness burns are painful, difficult to manage and can have a negative effect on quality of
life through scarring, permanent disfigurement and loss of function. The aim of burn treatment in partial thickness
burns is to save lives, stimulate wound healing by creating an optimumly moist wound environment, to have
debriding and analgesic effects, protect the wound from infection and be convenient for the patient and
caregivers. However, there is no consensus on the optimal treatment of partial thickness wounds. Flaminal® and
Flamazine® are two standard treatment options that provide the above mentioned properties in burn treatment.
Nevertheless, no randomized controlled study has yet compared these two common treatment modalities in partial
thickness burns. Thus, the aim of this study is to evaluate the clinical effectiveness, quality of life and cost-
effectiveness of Flaminal® versus Flamazine® in the treatment of partial thickness burns.
Methods/Design: In this two-arm open multi-center randomized controlled trial, 90 patients will be randomized
between Flaminal® and Flamazine® and followed for 12 months. The study population will consist of competent or
temporarily non-competent (because of sedation and/or intubation) patients, 18 years of age or older, with acute
partial thickness burns and a total body surface area (TBSA) of less than 30 %. The main study outcome is time to
complete re-epithelialization (greater than 95 %). Secondary outcome measures include need for grafting, wound
colonization/infection, number of dressing changes, pain and anxiety, scar formation, health-related quality of life
(HRQoL), and costs.
Discussion: This study will contribute to the optimal treatment of patients with partial thickness burn wounds and
will provide evidence on the (cost-)effectiveness and quality of life of Flaminal® versus Flamazine® in the treatment
of partial thickness burns.
Trial registration: Netherlands Trial Register NTR4486, registered on 2 April 2014.
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Background
Partial thickness burn wounds are painful, difficult to
manage, and susceptible to infection [1]. The aim of
burn treatment in partial thickness burns is to promote
rapid wound healing, decrease pain and suffering, pro-
tect the wound from infection, minimize scar formation
and functional impairment, and to enable patients to re-
turn to normal daily activities as soon as possible [2, 3].
Thus, an ideal dressing should stimulate wound healing
by creating an optimumly moist wound environment,
but also have a debriding and analgesic effect. Moreover,
an ideal dressing should protect the wound from infec-
tion and be convenient for the patient and caregivers.
Nowadays, many topical dressing materials are avail-
able for the treatment of superficial and deep partial
thickness burns, while there is no strong evidence to
support their use [4]. In clinical practice, silver-containing
dressings and topicals, in particular silver sulfadiazine
(SSD), have been the most commonly used burn wound
dressing in the treatment of partial thickness burns for
over 30 years [4–8].
The popularity of SSD can mainly be explained by its
antimicrobial effect in vitro against a wide range of gram-
positive and gram-negative microorganisms including re-
sistant forms such as methicillin-resistant Staphylococcus
aureus (MRSA) and vancomycin-resistant Enterococcus
(VRE), and against fungi and anaerobes [9–11]. However,
a Cochrane review of 26 randomized controlled trials
(RCTs) found insufficient evidence to establish whether
silver-containing dressings or topical agents prevent
wound infection more effectively compared to non-silver
containing treatments [12].
Several studies have shown that silver is highly toxic
to both keratinocytes and fibroblasts in in vitro models
[7, 13–15]. Other studies found that SSD will form a
pseudoeschar which can promote bacterial proliferation
and requires frequent removal or debridement on a daily
basis to facilitate re-epithelialization and the optimal as-
sessment of the wound state. In contrast, two other
studies found that some silver preparations are not toxic
and suggest positive effects of silver on wound healing
[16, 17]. A number of systematic reviews of clinical trials
showed that SDD is consistently associated with poorer
wound healing than non-silver treatment for superficial
and partial thickness burns [4, 18, 19]. However, the re-
sults of these reviews should be interpreted with caution
because of the high risk of bias in these clinical trials.
With regard to costs, a number of studies suggested that
SDD is less cost-effective than Mepilex® Ag, Aquacel® Ag
and Acticoat® [20–24].
Recently, Flaminal® (Flen Pharma, Kontich, Belgium)
was introduced onto the market. Flaminal® consists of
hydrated alginates polymers in a polyethyleneglycol
(PEG) matrix embedded with a biologic enzyme system
based on glucose oxidase and lactoperoxidase that are
stabilized by guaiacol [15]. This enzyme system forms
free radicals which destroy the cell wall of absorbed bac-
teria. Furthermore, short-chain PEG dissolves dry scab
and necrotic material which results in lysed material.
Wound exudate, including bacteria, and lysed material is
absorbed by alginates in hydrated form. These two steps
result in continuous debridement [25, 26].
Pre-clinical data by Vandenbulcke et al. and de Smet
et al. showed that Flaminal® Forte is not toxic to
keratinocytes and fibroblasts in vitro [15, 27]. In effect,
Flaminal® Forte may not damage skin cells which will fi-
nally result in undelayed wound healing. Two studies
have indicated a faster wound healing when a partial
thickness burn wound was treated with Flaminal® Forte
compared to SSD [28, 29]. But these results should be
interpreted with caution due to the retrospective design
of these studies. However, a shorter wound healing time
would not only reduce length of hospital stay (LOS) but
probably also scar formation since Deitch et al. and
Cubison et al. demonstrated that burn wounds which
heal within 21 days have less risk of developing hyper-
trophic scars and contractures [1, 30].
There are studies showing conflicting data with re-
spect to bacterial growth under Flaminal® Forte; with
some demonstrating count reductions [15, 27] while
others show increases [29].
Dressings with SSD should be changed every 24 hours,
and removing the pseudoeschar, which is a result of the
SSD base drying out, is usually painful. In contrast,
Flaminal® Forte can be applied every other day after the
third post-burn day (PBD) and can be removed easily
from the wound. However, the effect on pain perception
and anxiety during dressing changes between these
treatments have not yet been compared. Also, the effect
of both treatments on LOS, scarring and health-related
quality of life (HRQoL) are not known.
Finally, medical costs including those for medical staff,
materials for wound care, surgical procedures, hospital
stay, HRQoL, and productivity loss due to the burn injury
are unknown for both treatments. A cost-effectiveness ana-
lysis is thus mandatory to evaluate the long-term health
economic outcomes of the studied treatments and justify
the application of both treatments in clinical practice.
Objectives
The aim of this study is to evaluate the clinical effective-
ness, quality of life and cost-effectiveness of Flaminal®
versus Flamazine® (SSD) in the treatment of partial
thickness burns.
Method/Design
This investigator initiated, open label, multi-center, RCT
compares the effects of treatment and cost-effectiveness
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of Flaminal® Forte versus Flamazine® in the treatment of
partial thickens burns.
Study population
The study will be performed in two of the three burn cen-
ters (Beverwijk and Rotterdam) in The Netherlands. In
these burn centers, both Flaminal® and Flamazine® are
therapeutic options for treating partial thickness burns.
Patients who are admitted to the Beverwijk or Rotterdam
Burn Centre and who meet the following inclusion criteria
will be eligible for this study: competent or temporarily
non-competent (because of sedation and/or intubation);
partial thickness burns of minimally 1 % total body surface
area (TBSA) (possibly in combination with full thickness
burns); hospital admission within 48 hours of burn injury;
written informed consent by the patient. Patients meeting
one or more of the following criteria are excluded: age
below 18 years; TBSA of more than 30 %; burns caused by
chemicals, electricity or radiation; if local therapy with a
topical agent has already started; patients who are ex-
pected (according to the treating medical physician) to be
non-compliant with the study protocol.
Recruitment, consent and randomization
All patients who are admitted to the burn center
undergo standardized screening and baseline procedures
according to the local protocol. The local investigator
will check the inclusion and exclusion criteria of the
study and will inform the participant about the study. If
the participants are willing to participate in this study,
they must provide written informed consent. If an eli-
gible patient is temporarily non-competent because of
sedation and/or intubation, a legal representative of the
patient, according to the Dutch Medical Treatment Act
(WGBO), will be informed about the study and will pro-
vide written informed consent. After the sedation or in-
tubation has ended, the patient will be asked to confirm
willingness to participate in the study in writing, other-
wise the participation is discontinued and the collected
study data will be destroyed.
After informed consent has been obtained, the lar-
gest partial thickness area will be assigned as the
study area. Thereafter, the patient will be randomly
assigned to one of the two study arms using TenALEA
(Trans European Network for Clinical Trials Services), an
online randomization program (www.flam-studie.nl). The
online-randomization is stratified by center and uses vari-
ably sized blocks in a 1:1 ratio. In both participating hospi-
tals the local trial coordinator will receive a username and
password for online randomization. After randomization
the local trial coordinator of that center and the central
trial coordinator will receive an email with the inclusion
number and the randomization outcome. The outcome
will also be displayed on the website, only visible for the
randomizing local and central trial coordinators. Then, all
the burn wounds will be treated with the treatment that is
assigned by the randomization.
When the study area that was initially assessed as a
partial thickness burn, turns out to be a full thickness
burn area after performing laser Doppler imaging (LDI),
then the study area will be replaced: the second largest
partial thickness area (confirmed by LDI) will then be
chosen as the study area.
For practical reasons it is not possible to blind the pa-
tients. It is also impossible to blind the medical staff
who provide the burn wound care, because they are in-
volved in all aspects of the care and are able to recognize
each treatment from its appearance. No blinding of
other outcomes is also possible for the same reasons.
Interventions
The patient will be allocated to one of the following
treatments:
o Flaminal® Forte: treatment with Flaminal® Forte
(glucose oxidase-lactoperoxidase guaiacol complex of
50 g in 5.5 % alginogel) will be initiated within
24 hours after admission. Before applying Flaminal®
Forte on the wound, pain medication must be given.
Paracetamol, Oxynorm and Oxycontin will be used
as standard pain medication. The usage and doses of
pain medication will be monitored. The burn wound
will be cleaned and rinsed with Prontosan® followed
by careful dabbing and drying of the wound. The
wound will then be covered with a non-adhesive
dressing on which a sufficiently thick layer (4–5 mm)
of Flaminal® Forte has been applied. A net bandage/
dressing will be used to keep the dressing in place.
Dressing changes will be performed daily during the
first 3 days post burn and thereafter every other day.
If an infection is suspected, or in case of leaking or
insufficient gel, the dressing with Flaminal® Forte may
be changed daily after 3 days post burn. In case of
wound colonization or infection, treatment with
Flaminal® Forte will be changed to another relevant
treatment based on the results of the wound culture
o Flamazine®: treatment with Flamazine® (silver
sulfadiazine 10 mg/g in hydrophilic crème base) will
consist of daily washing and application of
Flamazine®. Before applying Flamazine® on the
wound, pain medication must be given. Paracetamol,
Oxynorm and Oxycontin will be used as standard
pain medication. The usage and doses of pain
medication will be monitored. The burn wound will
be cleaned and rinsed with Prontosan® followed by
carefully dabbing and drying of the wound. A
sufficiently thick layer (at least 2–3 mm) of
Flamazine® will be applied directly on the wound.
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The cream will be covered with a non-adhesive
dressing. A net bandage/dressing will be used to keep
the dressing in place. This procedure is repeated once
every 24 hours until the sixth day post burn.
Thereafter, the treatment of all patients in this
study arm will consist of Furacine Soluble Dressing
(Furacine 2 mg/g ointment) on the seventh day
post urn, and Flamazine® on the eighth day post
burn. Treatment with Furacine Soluble Dressing and
Flamazine® will be alternated until complete wound
healing/operation because of the cytotoxicity of the
silver particles in Flamazine® on the wound bed when
used continuously. In case of wound colonization or
infection the treatment will be replaced with another
relevant treatment based on the results of the wound
culture
After discharge, patients in both group will be treated
in an outpatient setting, according to the local protocol.
Outcome measures
Primary outcome
Primary endpoint is time to complete re-epithelialization
(greater than 95 %) of the study area, in days, judged by
two experienced burn specialists during each dressing
change. Complete re-epithelialization of the study area is




 Need for operation which is evaluated between 10
and 14 days post burn. Reasons for operation are
that the experienced burn specialist expects no
further wound healing in the next 7 to 11 days of
the partial thickness area or a full thickness burn. If
the decision to graft is made before 10 to 14 days
post burn then the operation will still performed
before 10th day post burn day. The only indication
for operation before the 10th PBD is when a partial
thickness burn becomes a full partial thickness burn.
The treatment of full thickness burns is split skin
graft in an early stage
 Percentage TBSA of the study area that covered
with skin graft
 Colonization: twice a week a wound swab will be
taken from the study area. The wound swab will
then be sent for laboratory investigation. In brief,
the analysis of the wound swab will include the
following steps. The microscopic examination will
entail gram-staining. Thereafter, a quantity of the
specimen will be cultured to obtain a pure single
specimen culture. Finally, the sensitivity of the
organisms to specific local therapy will be deter-
mined. In case of wound colonization the treatment
will be changed to another relevant treatment based
on the results of the wound culture
 Infection: infection is suspected if a combination of
skin redness, pain, swelling, tenderness, warmth,
fever or pus draining from the wound is present.
Infection is a clinical evaluation of the wound, in
presence of absence of positive wound culture, and
is judged by a physician at the burn center during
each dressing change
 Number of dressing changes
 Use of systemic antibiotics
o Patient-reported outcomes:
 Pain will be measured during the application and
removal of the wound dressing (procedural pain,
measured directly after dressing change) and
background pain (measured in the morning and
evening). Pain will be measured twice daily during
hospital admission by use of a Visual Analogue
Thermometer (VAT), which is a numeric scale from
0 (no pain) to 10 (worst imaginable pain)
 Itching will be measured daily in the evening during
hospital admission by use of a VAT [31]
 Anxiety: the Burn Specific Pain Anxiety Scale
(BSPAS) will be scored on day 7 ± 2 post burn and
on the day of discharge. The BSPAS is a valid and
reliable nine-item self-report scale for the assess-
ment of pain-related and anticipatory anxiety in
burned patients [32, 33]
 Health-related quality of life (HRQoL) will be
measured using the following questionnaires, in the
week before discharge and at 3, 6 and 12 months
post burn:
1. Burn-specific quality of life (QoL) will be measured
using the Dutch version of the Burn Specific Health
Scale (BSHS)–Brief [34, 35]. The BSHS-Brief is a
valid and reliable self-administered questionnaire
that covers nine domains (heat sensitivity, affect,
hand function, treatment regimens, work, sexuality,
interpersonal relationships, simple abilities, and body
image). The questionnaire takes 10–15 minutes to
complete and 5 minutes to score. Responses are
scored by the patient on a five-point scale from 0
(extreme) to 4 (none/not at all) for each of the 40
items. Mean scores are calculated for each of the
domains
2. General HRQoL will be measured using the
EuroQol-5D (EQ-5D) questionnaire [36]. This sim-
ple and generic description of health status is widely
used in studies on clinical and economic appraisal.
The EQ-5D outcomes will be converted in utility
scores between 0 (death) and 1 (perfect health)
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based on empirical valuations [37]. From the area
under the utility curve during the 12 months of
follow-up quality- adjusted life years (QALYs) will be
calculated
o Scar formation: the following aspects of scar
formation will be measured after 3, 6 and
12 months post burn:
 Scarring will be measured using the Patient and
Observer Scar Assessment Score (POSAS), a
valid and reliable scale that is designed for the
evaluation of all types of scars by professionals
and patients. It consists of two numeric scales:
the Patient Scar Assessment Scale which is
completed by the patient and the Observer Scar
Assessment Scale which is completed by the
medical staff. The variables scored by the patient
are pain, itching, color, stiffness, thickness and
irregularity [38–40]. The variables scored by the
medical staff include vascularization,
pigmentation, thickness, relief and pliability
 Elasticity will be measured using a Cutometer
(Courage & Khazak, Köln, Germany), a
validated instrument to measure the vertical
deformation of the skin in millimetres when the
skin is pulled by means of a controlled vacuum
into a circular aperture [41]
 Scar color and pigmentation will be measured
using the DSM II colorimeter
(Dermaspectrometer).This is a validated
instrument to measure scar color by a narrow-
band simple reflectance meter [41]
o Total (medical and non-medical) costs: total costs
in this study represent direct health care costs
(inpatient and outpatient medical costs), direct
non-healthcare costs and indirect non-health care
costs (productivity loss). Personnel time and used
materials for wound care and surgical procedures,
hospital days for initial stay and re-admittance
and outpatient visits during the first year will be
measured prospectively as part of the case record
form. Health resource use outside the hospital,
travel costs and productivity losses will be
recorded by questionnaires filled out by the
patients at 3, 6 and 12 months post burn. Cost of
dressing changes and surgical procedures will be
assessed by translating the personnel time and
used materials into costs by means of gross
salaries and market prices. The costs of hospital
stay and outpatient care in burn centers will be
calculated by multiplying the number of hospital
days respectively outpatient visits with their cost
prices [42]. Other healthcare use will be translated
into costs by standard prices [43]. Productivity
losses will be valued using the friction cost
method [44]
o Baseline parameters: age, gender, skin type,
wound etiology, bacterial contamination at
admission, location of the wound, type of
wound, TBSA% and co-morbidities. In all
patients, the burn depth of the study area will
be accurately determined on day 2–5 post burn
by clinical evaluation and LDI scan using the
moorLDI2-Burn Imager™ (Moor Instruments,
Axminster, UK) and, based on pre-defined
criteria (Table 1), be classified as superficial,
intermediate or deep partial thickness injury.
The size of each burn wound is then estimated
in TBSA. In a LDI the low-intensity laser beam
is scanned across a tissue surface in a raster
fashion using a moving mirror. There is no
direct contact with the tissue being assessed.
The wounds are scanned by a trained research
physician or nurse, after removal of topical
medication (during regular wound treatment).
All research physicians and nurses in both burn
centers have followed the same training sessions
and have the same experience. The scanning will
take 1–5 minutes.
Table 1 Clinical assessment and laser Doppler imaging (LDI) results
Classification Clinical properties LDI color










Pink-red, shiny and dry Mix of supple
and stiff





Red, shiny and dry Mix of supple
and stiff
>2 sec +/- >21 days or even no
spontaneous healing
Blue
Full thickness burns None White-yellow, red,
brown and black
Stiff >2 sec - No spontaneous
healing
Blue
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A schedule with baseline and outcome measurements
during the study is presented in Table 2.
Sample size calculation
The study is designed to demonstrate a clinically rele-
vant difference regarding time to complete epithelializa-
tion between the treatment arms. Based on a
retrospective study of 70 patients with superficial and
deep partial thickness burns of the hand, we expect
wounds to heal in 11 days on average with Flamazine®
and in 6 days on average with Flaminal® (pooled stand-
ard deviation 7.5 days) [28]. With alpha set at 5 %, 41
patients are needed in both intervention arms to detect
a difference in wound healing time with 80 % power. To
allow for 10 % attrition, a total of 90 patients will be in-
cluded in the study.
Statistical analysis
The analysis will be performed according to the
intention-to-treat principle. The baseline patient charac-
teristics will be described as mean ± standard deviation
for normally distributed continuous variables, as median
(range) for skewed continuous variables, and as number
(proportion) for categorical variables. Differences in time
to complete re-epithelialization will be compared in both
treatment groups will be analyzed with Kaplan-Meier
curves and log rank test.
If the baseline characteristics seem unbalanced despite
randomization, a multivariable Cox regression analysis
Table 2 Time schedule for study procedures and assessments
Procedure/Assessment Admission Treatment phase Follow-up (month)
3 6 12
Standard screening, baseline procedures x
Check eligibility (inclusion criteria) x
Provide patient Information x
Obtain written informed consent x x (confirmation by patients who were
initially non-competent)
Randomization (Flaminal® vs Flamazine®) x
Baseline parameters x
LDI x
Wound colonization x x
Wound healing At each dressing change
Need for surgery of partial and/or full thickness burns
and % of study area requiring skin graft
10–14 PBD
Colonization x Swabs on Mondays and Thursdays
Infection x Clinical judgment during dressing changes
Dressing changes x
Use of systemic antibiotics x
Pain and anxiety
Visual analogue thermometer (VAT) x Daily, before and after dressing change and
in the evening
Itching x Daily in the evening on 7th ±2 PBD and day
of discharge
Burn Specific Pain and Anxiety Score (BSPAS) x
Health-related quality of life (HRQoL) In the last week of hospitalization
Burn Specific Health Scale Brief (BSHS-Brief) In the last week of hospitalization x x x
EuroQol-5D (EQ-5D) x x x
Scarring
POSAS x x x
Cutometry x x x
Dermaspectrometry x x x
Costs Daily x x x
LDI laser Doppler imaging, PBD post-burn day
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will be performed to correct for potentially confounding
variables to confirm the primary analysis.
The secondary clinical and patient-reported outcomes
on specific follow-up moments will be compared be-
tween the treatment groups using the two-sided t test or
Mann-Whitney test for continuous data, and a two-
sided Chi-square test or Fisher’s exact test for categorical
data. Repeatedly measured study parameters such as
pain and quality of life will be also analyzed using a
linear mixed model with treatment as fixed effect and
patient as random effect. In the analyses, p values <0.05
will be considered statistically significant.
Economic evaluation
The economic analysis will be performed from the soci-
etal perspective. The follow-up period is 12 months. Due
to this short time frame, no discounting will take place.
Cost-effectiveness ratios will be calculated by dividing
the difference in average costs per patient between both
intervention groups by the difference in primary out-
come (time to complete re-epithelialization). Dressing
changes are reported to be one of the most painful and
traumatic aspects of burn treatment. This impact is not
measured in the primary outcome measure (time to
greater than 95 % re-epithelialization). In a sensitivity
analysis, therefore, the difference in costs will be related
to the difference in dressing changes between both
treatments.
Ethical consideration and safety
This study has been approved by the Medical Research
Ethics Committee of Noord-Holland (NL43671.094.13).
EudraCt number: 2013-000901-21. This study is also
registered in the Netherlands Trial Registry (NTR),
trial number 4486 and will be conducted in agreement
with the Declaration of Helsinki, version Fortaleza (Brazil),
October 2013, concerning the Ethical Principles for
Medical Research Involving Human Subjects, and in
accordance with the International Conference on
Harmonization (ICH) of Good Clinical Practice (GCP)
Guidelines and the valid Dutch laws. Adverse events
(AEs), serious adverse events (SAEs) and suspected
unexpected serious adverse reactions (SUSARs) are
documented and reported to the competent author-
ities. All AEs will be followed until they have abated,
or until a stable situation has been reached. Depend-
ing on the event, follow-up may require additional
tests or medical procedures as indicated, and/or refer-
ral to the general physician or a medical specialist.
There is no additional risk or discomfort for the pa-
tients in this study compared to daily practice. Since
most of the measurements and questionnaires used in
the study are also implemented in daily care of burn
patients in the Dutch burn centers, participation does
not involve a large extra burden for them.
Discussion
This randomized controlled study will enable a compari-
son of the effectiveness, cost-effectiveness and quality of
life of Flaminal® and Flamazine®, two common treatment
modalities for partial thickness burns.
An accurate diagnosis of the partial thickness burns
is essential in our study. Several studies have shown
that clinical evaluation of burn depth is highly
dependent on the experience of the clinician and that
experienced clinicians are accurate in about 50–75 %
of the cases [45–49]. Therefore, we use LDI, which
has an accuracy of 95 % in combination with clinical
evaluation of the wound, for measuring burn depth
[49–51]. Furthermore, in our study two experienced
wound specialists must agree on the time to complete
re-epithelialization in order to optimize the accuracy
of wound re-epithelialization. Bloemen et al. have
shown that experienced observers are able to evaluate
the re-epithelialization rate in a reliable and effective
way [52]. No digital analysis is required to evaluate
wound re-epithelialization since clinical evaluation by
an experienced burn specialist is as equally effective
as digital analysis [53].
This study will contribute to optimize the treatment of
patients with partial thickness burn wounds from both
the clinical and economical perspective.
Trial status
Recruitment started in February 2014, and was
completed on 20 October 2015. The follow-up of in-
cluded patients is ongoing. The planned end date of
the data collection is November 2016.
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